ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES
    2.
    发明申请
    ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES 审中-公开
    抗体设计使用抗脂质抗体水晶结构

    公开(公告)号:WO2010065921A2

    公开(公告)日:2010-06-10

    申请号:PCT/US2009/066862

    申请日:2009-12-04

    Abstract: The present invention provides crystalline forms of an anti-lipid antibody or fragment thereof, which may further comprise a lipid ligand of said antibody and/or salts, metals, or co-factors. Methods for making such crystals and co-crystals are provided. The lipid may be a bioactive lipid, including sphingolipids such as S1P. X-ray coordinates of such a crystal are provided, as are methods of using this information in antibody design or optimization. Methods for designing a humanized antibody to a lipid are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided.

    Abstract translation: 本发明提供抗脂质抗体或其片段的结晶形式,其可以进一步包含所述抗体和/或盐,金属或辅因子的脂质配体。 提供制造这种晶体和共晶的方法。 脂质可以是生物活性脂质,包括鞘脂如S1P。 提供这种晶体的X射线坐标,以及在抗体设计或优化中使用该信息的方法。 提供了设计人体对抗体的抗体的方法。 这些方法可以在硅胶中进行,并且可以旨在增强抗体与其原始靶脂质的结合亲和力和/或改变结合特异性。 还提供了通过这些方法产生的抗体。

    METHODS AND REAGENTS FOR DETECTING BIOACTIVE LIPIDS
    3.
    发明申请
    METHODS AND REAGENTS FOR DETECTING BIOACTIVE LIPIDS 审中-公开
    检测生物活性脂肪酸的方法和试剂

    公开(公告)号:WO2007140433A3

    公开(公告)日:2008-11-06

    申请号:PCT/US2007070015

    申请日:2007-05-31

    Abstract: Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1 -phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives. Methods for making such derivatized lipids, immunogens, and monoclonal antibodies and derivatives, methods for detecting such antibodies once generated, and therapeutic and diagnostic methods for using such antibodies and derivatives, are also described.

    Abstract translation: 描述了用于产生针对生物活性脂质靶标的反应性的单克隆抗体及其衍生物的组合物和方法。 这些组合物包括衍生的脂质,其中每一种都包含具有极性头基团和至少一个烃链的生物活性脂质(例如溶血磷脂酸或鞘氨醇-1-磷酸酯等溶血磷脂酸或鞘氨醇-1-磷酸酯),其中碳原子已经用 吊坠反应组; 通过将衍生的脂质与载体部分(例如载体蛋白,聚乙二醇,胶体金,藻酸盐或硅氧烷珠)连接而制备的免疫原; 通过用这种免疫原免疫动物产生的单克隆抗体和衍生物; 以及含有此类抗体和抗体衍生物的治疗和诊断组合物。 还描述了制备这种衍生化脂质,免疫原和单克隆抗体及其衍生物的方法,一旦产生的检测此类抗体的方法,以及使用这些抗体和衍生物的治疗和诊断方法。

    COMBINATIONS OF ANTI-S1P ANTIBODIES AND SPHINGOLIPID PATHWAY INHIBITORS
    6.
    发明申请
    COMBINATIONS OF ANTI-S1P ANTIBODIES AND SPHINGOLIPID PATHWAY INHIBITORS 审中-公开
    抗S1P抗体与丝氨酸途径抑制剂的组合

    公开(公告)号:WO2012057877A2

    公开(公告)日:2012-05-03

    申请号:PCT/US2011039200

    申请日:2011-06-04

    Abstract: Methods for administering combinations of compositions comprising anti-S1P antibodies or antibody fragments and modulators of sphingolipid metabolic pathway enzymes are described. Such methods allow aberrant or undesirable levels of S1P to be reduced in patients known or suspected to have a disease or disorder correlated with aberrant S1P levels, and thus will be useful in treating such diseases and disorders.

    Abstract translation: 描述了包含抗S1P抗体或抗体片段的组合物组合的神经鞘脂代谢途径酶的调节剂的方法。 这样的方法允许在已知或疑似患有与异常S1P水平相关的疾病或病症的患者中减少异常或不良水平的S1P,因此可用于治疗这些疾病和病症。

    ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES
    7.
    发明申请
    ANTIBODY DESIGN USING ANTI-LIPID ANTIBODY CRYSTAL STRUCTURES 审中-公开
    抗体设计使用抗脂质抗体水晶结构

    公开(公告)号:WO2010065921A3

    公开(公告)日:2011-12-29

    申请号:PCT/US2009066862

    申请日:2009-12-04

    Abstract: The present invention provides crystalline forms of an anti-lipid antibody or fragment thereof, which may further comprise a lipid ligand of said antibody and/or salts, metals, or co-factors. Methods for making such crystals and co-crystals are provided. The lipid may be a bioactive lipid, including sphingolipids such as S1P. X-ray coordinates of such a crystal are provided, as are methods of using this information in antibody design or optimization. Methods for designing a humanized antibody to a lipid are provided. These methods may be performed in silico and may be intended to enhance binding affinity of an antibody to its original target lipid, and/or to alter binding specificity. Antibodies produced by these methods are also provided.

    Abstract translation: 本发明提供抗脂质抗体或其片段的结晶形式,其可以进一步包含所述抗体和/或盐,金属或辅因子的脂质配体。 提供制造这种晶体和共晶的方法。 脂质可以是生物活性脂质,包括鞘脂如S1P。 提供这种晶体的X射线坐标,以及在抗体设计或优化中使用该信息的方法。 提供了设计人体对抗体的抗体的方法。 这些方法可以在硅胶中进行,并且可以旨在增强抗体与其原始靶脂质的结合亲和力和/或改变结合特异性。 还提供了通过这些方法产生的抗体。

    METHODS OF INCREASING NEURONAL DIFFERNTIATION USING ANTIBODIES TO LYSOPHOSHATIDIC ACID
    8.
    发明申请
    METHODS OF INCREASING NEURONAL DIFFERNTIATION USING ANTIBODIES TO LYSOPHOSHATIDIC ACID 审中-公开
    使用抗体对肉毒杆菌酸增加神经元差异的方法

    公开(公告)号:WO2011005581A2

    公开(公告)日:2011-01-13

    申请号:PCT/US2010039686

    申请日:2010-06-23

    CPC classification number: C07K16/44 A61K2039/505 C07K2317/76

    Abstract: Methods are provided for increasing neuronal differentiation of neuronal stem cells using antibodies that bind lysophosphatidic acid (LPA). Particularly preferred antibodies to LPA are monoclonal antibodies, including humanized monoclonal antibodies to LPA. Such antibodies, and derivatives and variants thereof, can be used in increasing neuronal differentiation, and in treatment and/or prevention of injuries, diseases, or conditions associated with insufficient neuronal differentiation and/or with elevated LPA levels in neural tissues.

    Abstract translation: 提供了使用结合溶血磷脂酸(LPA)的抗体来增加神经元干细胞的神经元分化的方法。 特别优选的LPA抗体是单克隆抗体,包括针对LPA的人源化单克隆抗体。 这些抗体及其衍生物和变体可用于增加神经元分化,以及治疗和/或预防与神经元分化不足和/或与神经组织中升高的LPA水平相关的损伤,疾病或病症。

Patent Agency Ranking